Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

MRNS has been the topic of several other reports. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

MRNS stock opened at $0.30 on Monday. The company has a market capitalization of $16.66 million, a PE ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a one year low of $0.26 and a one year high of $11.26. The company’s 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.31.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. Vanguard Group Inc. raised its position in shares of Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $813,000. Hussman Strategic Advisors Inc. raised its position in shares of Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Marinus Pharmaceuticals in the 2nd quarter worth about $206,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.